With growing bipartisan support and after debate in both the US House and Senate, Life Science companies recognize the BIOSECURE Act has strong support to pass. If enacted, it will prohibit US Federal Agencies and companies receiving federal funding to work with select Chinese Life Science companies.
Recent Posts
- Essential Medicines And The Need For A Robust U.S. Supply Chain
- BioSecure Act – 2024 Debate: Impact on US Life Science Companies with Chinese Suppliers
- Strategic CFO360 – How Procurement Efficiencies help drive growth
- Financial Leadership of Strategic Procurement
- Analysis Collaboration and Partnership
Recent Comments
No comments to show.
